Stocks Health care KALA

NASDAQ · Health care

KALA BIO, Inc. (KALA)

It posted a net loss of $10.1M. At June 30, 2026 it held $229K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 19, 2026.

What KALA BIO, Inc. does

KALA BIO, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker KALA.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What KALA BIO, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 24, 2026
   Proxy statement DEF 14A
2. September 11, 2026
   Preliminary proxy statement PRE 14A
3. September 10, 2026
   Material agreement 8-K
4. September 9, 2026
   Shareholder nomination deadline 8-K
5. August 28, 2026
   Stock exchange listing notice 8-K
6. August 19, 2026
   Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$21.32 versus -$85.64.
7. August 14, 2026
   Late quarterly report notice NT 10-Q
8. July 23, 2026
   Other event 8-K
9. July 22, 2026
   Securities offering prospectus 424B5
10. July 2, 2026
    Activist stake changed SCHEDULE 13D/A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on March 17, 2026. Insider transactions on SEC

Who owns KALA

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: Lazar David E. 3.9% (July 2, 2026); Baker Bros. Advisors LP 0.01% (May 15, 2026); Perceptive Advisors LLC 0% (November 14, 2025); Cormorant Asset Management, LP 0% (November 14, 2025); Point72 Asset Management, L.P. 0% (November 14, 2025).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

We have not read this company's Form 4 filings yet.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about KALA

What does KALA BIO, Inc. do?

KALA BIO, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker KALA.

Is KALA BIO, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $10.1M.

When did KALA BIO, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 19, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the proxy statement from September 24, 2026.

Similar companies

Compare KALA with

Compare KALA with any company

Follow KALA

Get an email when KALA BIO, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow KALA: get an email when it files

Where the numbers come from

Financial figures are the values KALA BIO, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.